These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21668921)

  • 1. Cognitive improvement with intrathecal administration of infliximab in a woman with Alzheimer's disease.
    Shi JQ; Wang BR; Jiang WW; Chen J; Zhu YW; Zhong LL; Zhang YD; Xu J
    J Am Geriatr Soc; 2011 Jun; 59(6):1142-4. PubMed ID: 21668921
    [No Abstract]   [Full Text] [Related]  

  • 2. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.
    Ivanoiu A; Sindic CJ
    Neurocase; 2005 Feb; 11(1):32-9. PubMed ID: 15804922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal Fluid from Alzheimer's disease patients promotes amyloid beta-protein oligomerization.
    Ikeda T; Ono K; Elashoff D; Condron MM; Noguchi-Shinohara M; Yoshita M; Teplow DB; Yamada M
    J Alzheimers Dis; 2010; 21(1):81-6. PubMed ID: 20413863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
    Donohue MC; Gamst AC; Aisen PS
    Alzheimers Dement; 2011 Mar; 7(2):245-6; author reply 247-9. PubMed ID: 21414558
    [No Abstract]   [Full Text] [Related]  

  • 5. Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease.
    Haldenwanger A; Eling P; Kastrup A; Hildebrandt H
    J Alzheimers Dis; 2010; 22(3):971-80. PubMed ID: 20858947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
    Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
    Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).
    Buerger K; Frisoni G; Uspenskaya O; Ewers M; Zetterberg H; Geroldi C; Binetti G; Johannsen P; Rossini PM; Wahlund LO; Vellas B; Blennow K; Hampel H
    Exp Gerontol; 2009 Sep; 44(9):579-85. PubMed ID: 19539742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Otto M; Kornhuber J; Rüther E; Wiltfang J
    Dement Geriatr Cogn Disord; 2011; 31(1):37-44. PubMed ID: 21135556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring cognitive change in Alzheimer's disease clinical drug trials.
    Harrison JE
    J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A screening UHPLC-MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species.
    Dillen L; Cools W; Vereyken L; Timmerman P
    Bioanalysis; 2011 Jan; 3(1):45-55. PubMed ID: 21175366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverse association between CSF Aβ 42 levels and years of education in mild form of Alzheimer's disease: the cognitive reserve theory.
    Dumurgier J; Paquet C; Benisty S; Kiffel C; Lidy C; Mouton-Liger F; Chabriat H; Laplanche JL; Hugon J
    Neurobiol Dis; 2010 Nov; 40(2):456-9. PubMed ID: 20656030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.
    Popp J; Lewczuk P; Frommann I; Kölsch H; Kornhuber J; Maier W; Jessen F
    J Alzheimers Dis; 2010; 22(2):459-68. PubMed ID: 21084733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissociation of β-amyloid from lipoprotein in cerebrospinal fluid from Alzheimer's disease accelerates β-amyloid-42 assembly.
    Takamura A; Kawarabayashi T; Yokoseki T; Shibata M; Morishima-Kawashima M; Saito Y; Murayama S; Ihara Y; Abe K; Shoji M; Michikawa M; Matsubara E
    J Neurosci Res; 2011 Jun; 89(6):815-21. PubMed ID: 21394760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial.
    Simons M; Schwärzler F; Lütjohann D; von Bergmann K; Beyreuther K; Dichgans J; Wormstall H; Hartmann T; Schulz JB
    Ann Neurol; 2002 Sep; 52(3):346-50. PubMed ID: 12205648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
    Wiig EH; Annas P; Basun H; Andreasen N; Lannfelt L; Zetterberg H; Blennow K; Minthon L
    Acta Neurol Scand; 2010 Mar; 121(3):186-93. PubMed ID: 19785641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
    Mollenhauer B; Esselmann H; Trenkwalder C; Schulz-Schaeffer W; Kretzschmar H; Otto M; Wiltfang J; Bibl M
    J Alzheimers Dis; 2011; 24(2):383-91. PubMed ID: 21297274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interest of CSF beta-amyloid1-42 and t-tau protein level determinations for the diagnosis of Alzheimer's disease].
    Smach MA; Charfeddine B; Lammouchi T; Dridi H; Ben Othman L; Bennamou S; Limem K
    Ann Biol Clin (Paris); 2008; 66(5):531-5. PubMed ID: 18957342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.